Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Determine the Safety and Efficacy of Oral Rivaroxaban and Standard Anticoagulant in the Treatment of Cerebrosinovenous Thrombosis in Children

NCT07523347 is registered in ClinicalTrials.gov with Muhammad Aamir Latif as lead sponsor.

NCT NCT07523347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07523347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Determine the Safety and Efficacy of Oral Rivaroxaban and Standard Anticoagulant in the Treatment of Cerebrosinovenous Thrombosis in Children
Lead sponsor
Muhammad Aamir Latif
Phase
Not applicable
Overall status
Completed
Start date
December 1, 2023
Completion date
December 31, 2025
Enrollment
75 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebrosinovenous thrombosis